PureTech Health plc (NASDAQ:PRTC – Get Free Report)’s share price gapped down before the market opened on Monday . The stock had previously closed at $28.47, but opened at $27.15. PureTech Health shares last traded at $27.15, with a volume of 465 shares changing hands.
PureTech Health Trading Down 3.8 %
The business has a 50 day simple moving average of $27.09 and a two-hundred day simple moving average of $23.95.
PureTech Health Company Profile
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies.
Featured Stories
- Five stocks we like better than PureTech Health
- Best Aerospace Stocks Investing
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- Stock Analyst Ratings and Canadian Analyst Ratings
- 3 Value Stocks You Can Buy Before They Become Big
- Best Stocks Under $5.00
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.